By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

European Commission (EC) 

Rue Joseph II
Jozef II straat 70
Brussels    B-1000  Belgium
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Medical Device






Company News
European Commission (EC) Approves IDELVION --CSL Behring's Novel Hemophilia B Treatment With Up To 14-Day Dosing Intervals 5/11/2016 11:17:28 AM
European Commission (EC) Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) + Yervoy (Ipilimumab) Regimen, for Treatment of Advanced Melanoma 5/11/2016 10:53:05 AM
European Commission (EC) Grants Marketing Authorization For Gilead (GILD)’s Fixed-Dose Combination Descovy (Emtricitabine, Tenofovir Alafenamide) For Treatment Of HIV 4/25/2016 10:08:35 AM
European Commission (EC) Approves Expanded Use Of Bristol-Myers Squibb (BMY)'s Opdivo (Nivolumab) To Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer 4/6/2016 11:05:08 AM
European Commission (EC) Approves Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) For Previously Treated Advanced Renal Cell Carcinoma 4/6/2016 11:02:49 AM
Takeda (TKPYY) Release: European Commission (EC) Approves Label Variation For ADCETRIS (Brentuximab Vedotin) To Include Data On Retreatment Of Adult Patients With Relapsed Or Refractory Hodgkin Lymphoma And Systemic Anaplastic Large Cell Lymphoma (sALCL) 1/22/2016 10:12:17 AM
European Commission (EC) Approves Amgen (AMGN)'s IMLYGIC (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe 12/18/2015 6:17:53 AM
Agendia BV And Partners Receive $6.8 Million From European Commission (EC) To Study Targeted Therapies For Colorectal Cancer 12/16/2015 8:16:51 AM
Horizon Pharma (HZNP) Receives European Commission (EC) Approval For RAVICTI (Glycerol Phenylbutyrate) Oral Liquid For The Treatment Of Urea Cycle Disorders In Patients Two Months Of Age And Older 12/1/2015 10:17:03 AM
Exelixis (EXEL) Announces European Commission (EC) Approval Of COTELLIC (Cobimetinib) For Use In Combination With Vemurafenib In Advanced BRAF V600 Mutation-Positive Melanoma 11/25/2015 10:36:06 AM
12345678910...
//-->